# UAB CF Research and Translation Core Center

> **NIH NIH P30** · UNIVERSITY OF ALABAMA AT BIRMINGHAM · 2021 · $1,113,749

## Abstract

PROJECT SUMMARY/ABSTRACT
The UAB P30 Research and Translation Core Center consolidates a large number of externally funded cystic
fibrosis (CF) research programs on our campus, building an innovative environment to pursue, advance, and
train in CF-related science. During the last funding period, the P30 made robust and important contributions to
multiple UAB laboratories of our Research Base of over 70 investigators pursuing research relevant to CFTR
modulation, CF pathogenesis, and therapeutic translation. By virtue of the NIH Center, translational research at
our Institution has greatly accelerated in the past five years, as has the breadth of investigators. The richness
of CF basic science at UAB has grown in parallel with this translational expansion, providing numerous
opportunities to exploit in the next funding period, and we have modified the structure of the Center accordingly
to take advantage of these opportunities.
The P30 Center has allowed investigators at UAB and collaborating sites to improve understanding of CF
disease mechanism and has furnished novel opportunities to aggressively apply this information towards
experimental therapeutics. This NIH Center includes three Biomedical Research Cores that help to organize
efforts of CF faculty towards the common and essential goal of helping individuals with CF and to train the next
generation of CF leaders. The Cores include: Core A: Cell Model and Assay Core (B Woodworth and GM
Solomon, Co-PIs); Core B: Animal Models Core (DM Bedwell, PI); and Core C: Clinical and Translational Core
(SM Rowe and A Gaggar, Co-PIs). Each Core provides leading-edge assays, specialized reagents and
techniques, and valued expertise. The P30 has also engaged new investigators through a Pilot and Feasibility
mechanism integral to Center vitality and has a tight integration with the UAB Center for Clinical and
Translational Science, enabling a robust training environment. In addition to providing a platform from which
junior and senior scientists are brought into the field, Pilot Projects serve as a means of rapidly testing exciting
advances, particularly from the perspective of clinical translation. Two Pilot and Feasibility Projects are
proposed: Project 1: V Thannickal, PI. “Mucus Viscoelasticity is Mediated by Oxidase Enzymes through
Oxidative Protein Crosslinking”; and Project 2: J Campos-Gomez, PI. “Engineered PF Phage to Treat
Pseudomonas aeruginosa Biofilm Infections”, capitalizing on the next era of innovative opportunities to
transform the disease. Through these scientific initiatives, the P30 has added value to a collaborative
environment for CF research at our Institution, and is well-positioned to continue in this capacity in the future,
with a major focus on therapeutic translation.

## Key facts

- **NIH application ID:** 10246443
- **Project number:** 5P30DK072482-15
- **Recipient organization:** UNIVERSITY OF ALABAMA AT BIRMINGHAM
- **Principal Investigator:** Steven Mark Rowe
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $1,113,749
- **Award type:** 5
- **Project period:** 2007-04-01 → 2023-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10246443

## Citation

> US National Institutes of Health, RePORTER application 10246443, UAB CF Research and Translation Core Center (5P30DK072482-15). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10246443. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*